Thanks for your interest in our work. The B+ rating means that, for adults with established cardiovascular disease or who are at high risk of cardiovascular events while being treated with statins, we have high certainty that Vascepa provides a small-to-substantial net health benefit. The rating reflects both the level of potential health benefit/harm associated with a treatment, as well as the degree of confidence we have in the evidence. B+ is a relatively good grade, compared to other treatments we assess.
In addition to assessing treatments’ clinical effectiveness, our reports also explore treatments’ economic value. And in this regard, our draft analysis currently suggests that Vascepa is highly cost-effective and fairly priced for the benefit it provides patients.
Separately, I see you are from St. Louis, as am I. Go Cards!
Regards,
David Whitrap VP, Communications Institute for Clinical and Economic Review 857-523-1219
Market Data 
Markets 
